Opaleye Management Inc. Invests $1.21 Million in Protalix Biotherapeutics Inc (PLX) Stock

Opaleye Management Inc. bought a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 4th quarter, Holdings Channel reports. The fund bought 1,825,000 shares of the company’s stock, valued at approximately $1,206,000.

A number of research firms have weighed in on PLX. HC Wainwright set a $5.00 target price on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Monday, February 12th. Zacks Investment Research raised shares of Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research report on Tuesday, October 24th. Finally, BidaskClub downgraded shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.

Protalix Biotherapeutics Inc (PLX) opened at $0.66 on Tuesday. The stock has a market capitalization of $323.33, a P/E ratio of -0.32 and a beta of 1.02. Protalix Biotherapeutics Inc has a twelve month low of $0.48 and a twelve month high of $1.51.

WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/20/opaleye-management-inc-invests-1-21-million-in-protalix-biotherapeutics-inc-plx-stock.html.

Protalix Biotherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Want to see what other hedge funds are holding PLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX).

Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply